(NASDAQ: DNTH) Dianthus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.69%.
Dianthus Therapeutics's earnings in 2026 is -$173,660,000.On average, 17 Wall Street analysts forecast DNTH's earnings for 2026 to be -$241,887,148, with the lowest DNTH earnings forecast at -$350,902,550, and the highest DNTH earnings forecast at -$153,256,784. On average, 17 Wall Street analysts forecast DNTH's earnings for 2027 to be -$270,286,256, with the lowest DNTH earnings forecast at -$415,725,769, and the highest DNTH earnings forecast at -$159,570,734.
In 2028, DNTH is forecast to generate -$309,093,815 in earnings, with the lowest earnings forecast at -$463,941,386 and the highest earnings forecast at -$188,844,502.